Neuroendocrine differentiation in stage D2 prostate cancers

International Journal of Urology

Volumn 15, Issue 5, 2008, Pages 423-428

  Kamiya, Naoto ^a   Suzuki, Hiroyoshi ^a   Kawamura, Koji ^a   Imamoto, Takashi ^a   Naya, Yukio ^a   Tochigi, Naobumi ^a   Kakuta, Yukio ^b   Yamaguchi, Kunio ^b   Ishikura, Hiroshi ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Chromogranin A; Neuro specific enolase; Neuroendocrine cells; Prostate cancer; Prostate specific antigen; Tumor markers

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROSECRETORY SYSTEMS; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS;

EID: 43049088451     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02015.x     Document Type: Article

References (27)

1. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 60 : 5857 61.
2. Bostwick DG, Grignon DJ, Hammond ME et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement. Arch. Pathol. Lab. Med. 1999 124 : 995 1000.
3. Ross JS, Sheehan CE, Dolen EM, Kallakury BV. Morphologic and molecular prognostic markers in prostate cancer. Adv. Anat. Pathol. 2002 9 : 115 28.
4. Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin. Urol. Oncol. 1998 16 : 106 17.
5. 2 prostate cancer. Endocr. J. 2001 48 : 573 8.
6. Abrahamsson PA. Neuroendocrine differentiation in prostate carcinoma. Prostate 1999 39 : 135 48.
7. Abrahamsson PA. Neuroendocrine cells in tumor growth of the prostate. Endocr. Relat. Cancer 1999 6 : 503 19.
8. Di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992 70 : 254 68.
9. Di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an up-date. Prostate Suppl. 1998 8 : 74 9.
10. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum makers reflect immunohistochemical findings? Prostate 1997 30 : 1 6.
11. Berruti A, Dogliotti L, Mosca A et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000 88 : 2590 7.
12. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997 31 : 110 17.
13. Kamiya N, Akakura K, Suzuki H et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur. Urol. 2003 44 : 309 14.
14. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy in prostate cancer. J. Urol. 2002 167 : 512 13.
15. Cussenot O, Villette JM, Valeri A et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J. Urol. 1996 155 : 1340 3.
16. Lilleby W, Paus E, Skovlund E, Fossa SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001 46 : 126 33.
17. Tarle M, Frkovic-Grazio S, Kraljic I, Kovacic K. A more staging of advanced prostate cancer routine recognition of malignant endocrine structure: the assessment of serum TPS, PSA, and NSE values. Prostate 1994 24 : 143 8.
18. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J. Urol. 1991 146 : 358 61.
19. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl. 1998 8 : 43 51.
20. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988 61 : 195 202.
21. Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO Jr. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994 74 : 1899 903.
22. Allen FJ, Van Velden DJ, Heyns CF. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br. J. Urol. 1995 75 : 751 4.
23. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br. J. Urol. 1997 80 : 287 90.
24. Kaiser E, Kuzmits R, Pregant P, Burghuber O, Worofka W. Clinical biochemistry of neuro specific enolase. Clin. Chim. Acta 1989 183 : 13 31.
25. Buamah PK, Drake SR, Smedley HM, Bodger WA, Skillen AW. Neuron-specific enolase during chemotherapy of small cell lung cancer. J. Surg. Oncol. 1990 44 : 1 4.
26. Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M. The chromogranin-A (CgA) in prostate cancer. Arch. Gerontol. Geriatr. 2006 43 : 117 26.
27. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch. A Pathol. Anat. Histopathol. 1993 423 : 291 4.